Binding affinity and quantity of estrogen receptor in peripheral blood monocytes of patients with systemic lupus erythematosus

Lupus

Volumn 5, Issue 3, 1996, Pages 227-231

  Suenaga, R ^a   Mitamura, K ^a   Evans, M J ^a   Abdou, N I ^a  

^a ST LUKE S HOSPITAL   (United States)

Author keywords

Estrogen receptor; Lupus; Monocyte

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR;

ADHERENT CELL; ADULT; ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DISSOCIATION CONSTANT; FEMALE; FOLLICULAR PHASE; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL; RECEPTOR AFFINITY; SCATCHARD PLOT; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0029887061     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/096120339600500311     Document Type: Article

References (30)

1. Ahmed SA, Talal N. Importance of sex hormones in systemic lupus erythematosus. In: Wallace DJ and Hahn BH, eds. Dubois' Lupus Erythematosus. Philadelphia: Lea & Febiger, 1993: 148-156.
2. Lahita RG. The importance of estrogen in systemic lupus erythematosus. Clin Immunol Immunopathol 1992; 63: 17-18.
3. Steinberg AD, Melez KA, Raveche ES et al. Approach to the study of the role of sex hormones in autoimmunity. Arthritis Rheum 1979; 22: 1170-1176.
4. Roubmian JR, Talal N, Greenspan JS, Siiteri PK. Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies and glomerulonephritis in NZB/NZW F1 mice. J Exp Med 1983; 147: 1568-1583.
5. Carlsten H et al. Estrogen accelerates immune complex glomerulonephritis but ameliorates T cell-mediated vasculitis and sialadenitis in autoimmune MRL 1pr/1pr mice. Cell Immunol 1992; 144: 190-202.
6. Bole GGJ, Friedlaender MH, Smith CK. Rheumatic symptoms and serological abnormalities induced by oral contraceptives. Lancet 1969; February 15: 323-326.
7. Kay DR, Bole GG, Ledger WJ. Antinuclear antibodies, Rheumatoid factor and C-reactive protein in serum of normal woman using oral contraceptives. Arthritis Rheum 1971; 14: 239-248.
8. Tarzy BJ et al. Rheumatic disease, abnormal serology and oral contraceptives. Lancet 1972; September 9: 501-503.
9. Travers RL, Hughes RV. Oral contraceptive therapy and systemic lupus erythematosus. J Rheumatol 1978; 5: 448-451.
10. Garovich M, Agudelo C, Pisko E. Oral contraceptives and systemic lupus erythematosus. Arthritis Rheum 1980; 23: 1396-1398.
11. Lahita RG, Bradlow HL, Kunkel HG, Fishman J. Increased 16 alpha hydroxylation of estradiol in systemic lupus erythematosus. J Clin Endocrinol Metab 1981; 53: 174-178.
12. Junger P et al. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 618-623.
13. Buyon JP, Abramson S, Belmont HM. Past and present usage of oral contraceptives and hormonal replacement in women with SLE. Arthritis Rheum 1993; 36: S229 (Abstract C250).
14. Ben-Chetrit A, Ben-Chetrit E. Systemic lupus erythematosus indued by ovulation induction treatment. Arthritis Rheum 1994; 37: 1614-1617.
15. Distelhorst CW. Steroid hormone receptors. J Lab Clin Med 1993; 122: 241-244.
16. Markaverich BM, Williams M, Upchurch S, Clark JH. Heterogeneity of nuclear estrogen-binding sites in the rat uterus: A simple method for quantitation of type I and type II series by [3H]estradiol exchange. Endocrinol 1981; 109: 62-69.
17. Cohen JHM et al. Sex steroid receptors in peripheral T cells: Absence of androgen receptors and restriction of estrogen receptors to OKT8-positive cells. J Immunol 1983; 131: 2767-2771.
18. Weusten JJAM et al. Presence of oestrogen receptors in human blood mononuclear cells and thymocyte. Acta Endocrinol 1986; 112: 409-414.
19. Wada K et al. Estrogen binding sites in peripheral blood monocytes and effects of danazol on their sites in vitro. Gen Pharmac 1992; 23: 693-700.
20. Cutolo M et al. Presence of estrogen-binding sites on macrophage-like synoviocytes and CD8+, CD29+, CD45RO + T lymphocytes in normal and rheumatoid synovium. Arthritis Rheum 1993; 36: 1087-1097.
21. Uchiyama T, Inoue K, Nishioka J. Expression of estrogen receptor related protein (p 29) and estradiol binding in human arthritic synovium. J Rheumatol 1995; 22: 421-426.
22. Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25: 1271-1277.
23. Bombardier C et al. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640.
24. Mitamura K et al. Impaired tumor necrosis factor-α (TNF-α) production and abnormal B cell response to TNF-α in patients with systemic lupus erythematosus. Clin Exp Immunol 1991; 85: 386-391.
25. Crabtree GR, Smith KA, Munck A. Glucocorticoid Receptors. In: Catovsky D, Chanarin I, Beutler E, Eb B and Jacobs A, eds. The leukemic cell. New York: Churchill Livingston Inc., 1981: 252-269.
26. Scatchard G. The attraction of proteins for small molecules and ions. Ann NY Acad Sci 1949; 51: 660-672.
27. Horwitz DA, Stohl W. T lymphocytes, cytokines, and immune regulation in systemic lupus erthematosus. In: Wallace DJ and Hahn BH (eds). Dubois' Lupus Erythematosus. Philadelphia: Lea & Febiger, 1993: 83-96.
28. Flynn A. Expression of Ia and the production of interleukin-1 by peritoneal exudate macrophages activated in vivo by steroids. Life Sciences 1986; 38: 2455-2460.
29. Hu SK, Mitcho YL, Rath NC. Effects of estradiol on interleukin I syntehsis by macrophages. Int J Immnopharmacol 1988; 10: 247-252.
30. Shear HL, Roubinian JR, Gu P, Talal N. Clearance of sensitized erythrocytes in NZB/NZW mice: Effects of castration and sex hormone treatment. Eur J Immunol 1981; 11: 776-780.